US health panel recommends easing restrictions on controversial peptides
A federal health advisory panel has recommended easing FDA restrictions on several controversial peptides, despite warnings from government scientists regarding safety and efficacy. The move is expected to be supported by health secretary Robert F. Kennedy Jr., potentially leading to increased marketing of these substances for wellness and cosmetic use.
Why it matters
This decision signals a potential shift in federal regulatory oversight toward more permissive access to unproven health supplements, influenced by industry-linked panel members.
The panel voted 8-6 in favor of putting the peptides on FDA’s list of substances considered safe for pharmacy compounding. The panel voted 8-6 in favor of putting the peptides on FDA’s list of substances considered safe for pharmacy compounding. Trump administration US health panel recommends easing restrictions on controversial peptides Vote from advisory group – whose members include people linked to peptides industry – likely to embolden RFK Jr
Prefer the Guardian on Google A panel of federal health advisers on Thursday narrowly recommended easing access to several peptides popular with wellness influencers and celebrities, despite warnings from government scientists that the chemicals have not been shown to be safe or effective.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in